Bayer seeks European approval for darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, October 16, 2024, 13:00 Hrs [IST] ...
Medpage Today on MSN4d
Radioligand Shows Promise in Metastatic Hormone-Sensitive Prostate CancerIn metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen ...
DelveInsight's 'Metastatic Castration-Sensitive Prostate Cancer Pipeline Insight 2024' report provides comprehensive global ...
Bayer is seeking EMA approval for darolutamide in metastatic hormone-sensitive prostate cancer, building on promising Phase ...
Bayer announced the submission of an application to the European Medicines Agency for the oral androgen receptor inhibitor ...
Orion's collaboration partner Bayer submits application for third indication of darolutamide in the EU ...
Using progesterone receptor (PR)- and androgen receptor (AR)-mediated transactivation, we adapted a method that easily evaluates enzymatic activity of HSD3B2 by quantifying the conversion from ...
In the trial, a TALZENNA plus XTANDI combination regimen offered overall survival (OS) improvement in metastatic ...
Pfizer announces positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC: New York Friday, October 11, 2024, 09:00 Hrs [IST] Pf ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of ...
According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...
US pharma giant Pfizer today released positive top line results from the final prespecified overall survival (OS) analysis of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback